Cullinan Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Cambridge, MA
CGEM chart
What traders are saying about $CGEM
Latest postsCullinan Therapeutics, Inc. news
- Cullinan Therapeutics gains FDA clearance for velinotamig blood-disorder trial
Mugglehead Investment Magazine ·
- Cullinan Therapeutics starts Phase 1b/2a trial of velinotamig for blood disorders
StreetInsider ·
- Cullinan Therapeutics starts global Phase 1b/2a trial of velinotamig for autoimmune blood disorders after FDA clearance
Pluang ·
- Cullinan Therapeutics receives clearance for global Phase 1 2 study of velinotamig
Traders Union ·
- Cullinan Therapeutics Advances Velinotamig into Global
GlobeNewswire ·
- Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA
Yahoo Finance ·
- U.S. and Australian regulators clear a drug trial for two autoimmune blood disorders.
Stock Titan ·
- Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Has Consensus Price Target of $33.71 According to Brokerages
MarketBeat ·
- Cullinan Therapeutics (NASDAQ:CGEM) Rating Lowered to "Sell" at Wall Street Zen
MarketBeat ·
- Cullinan Therapeutics, Inc. Estimates – NASDAQ:CGEM
TradingView ·
- Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 6.7% - What's Next?
MarketBeat ·
- CGEM Stock Price, Quote & Chart
ChartMill ·
Cullinan Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | $0 |
| Net income | -$219.9M | -$167.6M | -$155.1M | $111.2M |
| Diluted EPS | – | – | $-3.69 | $2.38 |
| Total assets (year end) | $448.4M | $621.8M | $484.2M | $561.1M |
| Cash and equivalents (year end) | $88.3M | $83.0M | $98.4M | $156.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Cullinan Therapeutics, Inc.
- Ticker
- CGEM (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Cambridge, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1789972
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
Frequently asked questions
What exchange is Cullinan Therapeutics, Inc. listed on?
Cullinan Therapeutics, Inc. trades on the Nasdaq under the ticker symbol CGEM.
What industry is Cullinan Therapeutics, Inc. in?
Cullinan Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Cullinan Therapeutics, Inc. headquartered?
Cullinan Therapeutics, Inc.'s business address on file with the SEC is in Cambridge, MA.
When does Cullinan Therapeutics, Inc.'s fiscal year end?
Cullinan Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Cullinan Therapeutics, Inc. report?
Cullinan Therapeutics, Inc. reported $0 in revenue for calendar year 2022, according to its SEC filings.